Intervention not reported
Adverse events related to RIPC · patients undergoing a surgical intervention that induces kidney injury
The intervention showed no clear difference in adverse events related to RIPC (high certainty).
1 finding from 1 review
RR 3.47 [0.55, 21.76]
Studies not reported
High
Risk for at least one adverse event per patient · patients with the treatment of cocaine dependence
Amantidine showed no clear difference in adverse events as N of participants with at least one adverse event compared with antidepressants (low certainty).
1 finding from 1 review
Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events – cardiovascular · people with MCI
The intervention showed no clear difference in adverse events – cardiovascular (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events: skin irritation · older people
1 finding from 1 review
Surgery‐related adverse events: short‐term postoperative complications · premenopausal women undergoing hysterectomy for benign gynaecological indications
It is very uncertain whether hysterectomy with opportunistic salpingectomy changes surgery‐related adverse events: short‐term postoperative complications compared with hysterectomy without opportunistic salpingectomy (very low certainty).
1 finding from 1 review
Serious adverse events by week 8 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in serious adverse events by week 8 compared with placebo (low certainty).
1 finding from 1 review
All‐cause serious adverse events · the promotion of growth and prevention of infections in infants less than six months of age
Efficacy and safety of a first dose of whole‐cell pertussis vaccine showed no clear difference in all‐cause serious adverse events compared with a first dose of acellular pertussis vaccine (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related adverse events · children or adults with hemophilia A or B
1 finding from 1 review
Adverse events Post‐intervention · adults with neuropathic pain
It is very uncertain whether herbal treatment changes adverse events Post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
Treatment related adverse events · Patients undergoing any type of surgery under general anaesthesia receiving ACEIs or ARBs perioperatively
1 finding from 1 review
Intervention not reported
Incidence of skin adverse events · children (age < 18 years) susceptible to acute respiratory tract infections (ARTIs)
1 finding from 1 review
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 1.41 [0.81, 2.47]
Studies not reported
Low
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether higher‐dose heparin changes adverse events (thrombocytopenia) compared with standard‐dose heparin (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review